SRD5A1 and neoplasm: Both finasteride (SRD5A1 inhibitor) and dutasteride (dual SRD5A1/SRD5A2 inhibitor) have been shown in chemoprevention trials to give rise to a reduction in tumor incidence but also cause an increase in high-grade disease as determined by Gleason grade[101,102].